A prospective randomized controlled trial of metoclopramide combined with triple antiemetic therapy to prevent anthracycline-based chemotherapy-induced nausea and vomiting in patients with breast cancer
Abstract
Background: Triple antiemetic therapy, such as a 5-HT3 receptor antagonist (5H3-RA), aprepitant and dexamethasone, is recommended for the prophylaxis of highly emetogenic chemotherapy induced nausea and vomiting in patients with breast cancer. In the present study, we aimed to verify whether adding metoclopramide to the triplet antiemetic therapy is superior to the triplet antiemetic therapy in preventing CINV in patients with breast cancer....
Paper Details
Title
A prospective randomized controlled trial of metoclopramide combined with triple antiemetic therapy to prevent anthracycline-based chemotherapy-induced nausea and vomiting in patients with breast cancer
Published Date
Oct 1, 2018
Journal
Volume
29
Pages
viii610 - viii610
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History